Mucosal healing in pediatric Crohn's disease: the goal of medical treatment.
D'Haens
Geert
G
Department of Gastroenterology, Imelda General Hospital, Imeldalan 9, 2820 Bonheiden, Belgium.
D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology*; D018450:Disease Progression; D004351:Drug Resistance; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000473:pathology*; D011788:Quality of Life; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D001379:Azathioprine